Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 12 , ISSUE S1 ( July, 2022 ) > List of Articles


Work-up for Incidentally Detected NAFLD: How Far is It Worth?

Saurabh Mishra, Harish Bhujade, Amna Subhan Butt

Keywords : Acoustic radiation force impulse, Incidental NAFLD, Liver fibrosis, Metabolic (Dysfunction)-associated fatty liver disease, Magnetic resonance imaging-proton density fat fraction, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Transient elastography

Citation Information :

DOI: 10.5005/jp-journals-10018-1364

License: CC BY-NC 4.0

Published Online: 10-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


The incidence of nonalcoholic fatty liver disease (NAFLD) has seen a steep rise in parallel with the global obesity and metabolic syndrome epidemic. The presence of NAFLD contributes to significant socioeconomic burden due to healthcare costs, progression of liver disease as non-alcoholic steatohepatitis (NASH), and later cirrhosis and hepatocellular carcinoma (HCC). With the advent of widely available imaging, it is also being detected as an incidental diagnosis in individuals with systemic disease like metabolic syndrome, diabetes, chronic cardiac disease, polycystic ovarian syndrome, etc. or in asymptomatic persons on presurgical evaluation or even annual health assessments. Gastroenterologists, hepatologists, physicians and surgeons need to be updated about the new diagnostic criteria of Metabolic (dysfunction)-associated fatty liver disease, noninvasive tests (NITs) of liver fibrosis, new tools of elastography, and identification of those with high-risk disease. In this review, we appraise the relevance of new diagnostic definitions, steatosis and fibrosis estimation tests, advanced imaging like magnetic resonance elastography and proton density fat fraction and discuss the diagnostic algorithm for incidentally detected NAFLD.

PDF Share
  1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357. DOI: 10.1002/hep.29367.
  2. Duseja A, Singh SP, Saraswat VA, et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the study of the liver, endocrine society of India, Indian college of cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 2015;5(1):51–68. DOI: 10.1016/j.jceh.2015.02.006.
  3. Zhai M, Liu Z, Long J, et al. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep 2021;11(1):1–9. DOI: 10.1038/s41598-021-84577-z.
  4. Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014–2019. JAMA Netw Open 2020;3(2):e1920294. DOI: 10.1001/jamanetworkopen.2019.20294.
  5. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4(5):389–398. DOI: 10.1016/S2468-1253(19)30039-1.
  6. Duseja A, Najmy S, Sachdev S, et al. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open 2019;3(2):133. DOI: 10.1002/jgh3.12117.
  7. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13(4):643–654.e9. DOI: 10.1016/j.cgh.2014.04.014.
  8. Le TA, Loomba R. Management of non-alcoholic fatty liver disease and steatohepatitis. J Clin Exp Hepatol 2012;2(2):156–173. DOI: 10.1016/S0973-6883(12)60104-2.
  9. De A, Duseja A. Nonalcoholic fatty liver disease: Indian perspective. Clin Liver Dis 2021;18(3):158–163. DOI: 10.1002/cld.1141.
  10. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209. DOI: 10.1016/j.jhep.2020.03.039.
  11. Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int 2013;7:S755–S764. DOI: 10.1007/s12072-013-9480-x.
  12. Adam R, Karam V, Cailliez V, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018;31(12):1293–1317. DOI: 10.1111/tri.13358.
  13. Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Reports 2020;2(6):100192. DOI: 10.1016/j.jhepr.2020. 100192.
  14. Singh S, Kuftinec GN, Sarkar S. Non-alcoholic fatty liver disease in South Asians: a review of the literature. J Clin Transl Hepatol 2017;5:76. DOI: 10.14218/JCTH.2016.00045.
  15. Singh SP, Singh A, Misra D, et al. Risk factors associated with non-alcoholic fatty liver disease in Indians: a case-control study. J Clin Exp Hepatol 2015;5(4):295–302. DOI: 10.1016/j.jceh.2015.09.001.
  16. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England) 2004;363(9403):157–163. DOI: 10.1016/S0140-6736(03) 15268-3.
  17. Singh SP, Kar SK, Panigrahi MK, et al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. Trop Gastroenterol 2013;34(3):144–152. DOI: 10.7869/tg.118.
  18. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999–2014.e1. DOI: 10.1053/j.gastro.2019.11.312.
  19. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2021;73(3):1194–1198. DOI: 10.1002/hep.31420.
  20. Dinani AM, Lewis S, Branch AD, et al. Working up an incidental finding of hepatic steatosis on imaging. Clin Liver Dis 2020;16(2):58–62. DOI: 10.1002/cld.926.
  21. Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol 2009;8(4):346–352. PMID: 20009134.
  22. Manuel Echevarría J, León P, Pozo F, et al. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63(1):237–264. DOI: 10.1016/j.jhep.2015.04.006.
  23. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33(11):1098–1104. DOI: 10.1053/hupa.2002.129419.
  24. Monelli F, Venturelli F, Bonilauri L, et al. Systematic review of existing guidelines for NAFLD assessment. Hepatoma Res 2021;7:25. DOI: 10.20517/2394-5079.2021.03.
  25. Berzigotti A, Tsochatzis E, Boursier J, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update. J Hepatol 2021;75(3):659–689. DOI: 10.1016/j.jhep.2021.05.025.
  26. Huang X, Xu M, Chen Y, et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine (United States) 2015;94:e1682. DOI: 10.1097/MD.0000000000001682.
  27. SH K, JM L, JH K, et al. Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images–initial experience. Radiology 2005;234(3):793–803. DOI: 10.1148/radiol.2343040142.
  28. Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32(6):902–910. DOI: 10.1111/j.1478-3231.2012.02781.x.
  29. De Lédinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014;60(5):1026–1031. DOI: 10.1016/j.jhep.2013.12.018.
  30. Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004;230(1):276–280. DOI: 10.1148/radiol.2301021176.
  31. Festi D, Schiumerini R, Marzi L, et al. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013;37(4):392–400. DOI: 10.1111/apt.12186.
  32. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;152:598–607.e2. DOI: 10.1053/j.gastro.2016.10.026.
  33. Adams LA, Chan WK. Noninvasive tests in the assessment of NASH and NAFLD fibrosis: now and into the future. Semin Liver Dis 2020;40(4):331–338. DOI: 10.1055/s-0040-1713006.
  34. Ajmera V, Park CC, Caussy C, et al. Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2018;155(2):307–310.e2. DOI: 10.1053/j.gastro.2018.04.014.
  35. Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol 2019;29(7):3564. DOI: 10.1007/s00330-019- 06072-4.
  36. Patel J, Bettencourt R, Cui J, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016;9(5):692–701. DOI: 10.1177/1756283X16656735.
  37. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 2016;65(2):1006. DOI: 10.1016/j.jhep.2016.06.005.
  38. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289–293. DOI: 10.1002/hep.510240201.
  39. Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020;9(4):1005. DOI: 10.3390/cells9041005.
  40. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846–854. DOI: 10.1002/hep.21496.
  41. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317–1325. DOI: 10.1002/hep.21178.
  42. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53(3):726–736. DOI: 10.1002/hep.24105.
  43. Irvine KM, Wockner LF, Shanker M, et al. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int 2016;36(3):370–377. DOI: 10.1111/liv.12896.
  44. Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol 2019;71(2):389–396. DOI: 10.1016/j.jhep.2019.04.020.
  45. Ozturk A, Grajo JR, Dhyani M, et al. Principles of ultrasound elastography. Abdom Radiol (New York) 2018;43(4):773. DOI: 10.1007/s00261-018-1475-6.
  46. Siddhiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17(1):156–163.e2. DOI: 10.1016/j.cgh.2018.04.043.
  47. Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67(1):134–144. DOI: 10.1002/hep.29489.
  48. Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int 2021;41(2):261–270. DOI: 10.1111/liv.14669.
  49. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5(4):362–373. DOI: 10.1016/S2468-1253(19)30383-8.
  50. De A, Keisham A, Mishra S, et al. FibroScan-AST (FAST) score for nonalcoholic steatohepatitis–validation in an Indian cohort. J Clin Exp Hepatol 2021;0. DOI: 10.1016/j.jceh.2021.06.008.
  51. Boursier J, Anty R, Vonghia L, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 2018;47(10):1387–1396. DOI: 10.1111/apt.14621.
  52. Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020;17(7):387–388. DOI: 10.1038/s41575-020-0316-6.
  53. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68(2):268–279. DOI: 10.1016/j.jhep.2017.09.003.
  54. Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol 2017;15(4):474–485. DOI: 10.1016/j.cgh.2016.08.028.
  55. Duseja A, Singh SP, Mehta M, et al. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2022. DOI: 10.1089/met.2021.0104.
  56. Eslam M, Chen F, George J. NAFLD in lean Asians. Clin Liver Dis (Hoboken). 2021;16(6):240–243. Published 2021 Jan 13. DOI: 10.1002/cld.930.
  57. Sharma M, Premkumar M, Kulkarni AV, et al. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol 2021;9(1):40–50. DOI: 10.14218/JCTH.2020.00055.
  58. Duseja A, Dhiman RK, Premkumar M. Nonalcoholic fatty liver disease: lessons learnt in the last five years. J Clin Exp Hepatol 2021;11(2):159–162. DOI: 10.1016/j.jceh.2020.07.008.
  59. Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279–297. DOI: 10.1038/s41575-020-0269-9.
  60. Premkumar M, Kedarisetty CK. Cytokine storm of COVID-19 and its impact on patients with and without chronic liver disease. J Clin Transl Hepatol 2021;9(2):256–264. DOI: 10.14218/JCTH.2021.00055.
  61. World Health Organization. WHO global strategy on diet, physical activity and health. Available from: [Last accessed October 24, 2021].
  62. World Health Organization. Global action plan on physical activity 2018–2030: more active people for a healthier world. Available from: [Last accessed October 24, 2021].
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.